Evidence-based recommendations for successful Helicobacter pylori treatment

References

• Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 61(5), 646–664 (2012).
   Google Scholar
• Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1), 34–42 (2013).
   PubMed Web of Science ®Google Scholar
• Megraud F. Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug. Resist. Updat. 4(3), 178–186 (2001).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment. Pharmacol. Ther. 34(11–12), 1255–1268 (2011).
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59(8), 1143–1153 (2010).
   PubMed Web of Science ®Google Scholar
• Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 5(6), 321–331 (2008).
   PubMedGoogle Scholar
• Megraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 4(6) doi:10.4161/gmic.25930 (2013) (Epub ahead of print).
   Google Scholar
• McColl KE. Clinical practice. Helicobacter pylori infection. N. Engl. J. Med. 362(17), 1597–1604 (2010).
   PubMed Web of Science ®Google Scholar
• Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 378(9790), 507–514 (2011).
   PubMed Web of Science ®Google Scholar
• Liou JM, Chen CC, Chen MJ et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 381(9862), 205–213 (2013).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 34(6), 604–617 (2011).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment. Pharmacol. Ther. 24(10), 1469–1474 (2006).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after Helicobacter pylori treatment failure. Helicobacter 12(1), 68–73 (2007).
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. (2013) (Epub ahead of print).
   Google Scholar
• Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56(6), 772–781 (2007).
   Google Scholar
• Malfertheiner P, Megraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur. J. Gastroenterol. Hepatol. 9(1), 1–2 (1997).
   Google Scholar
• Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 147(8), 553–562 (2007).
   PubMed Web of Science ®Google Scholar
• Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 8(2), 79–88 (2011).
   PubMed Web of Science ®Google Scholar
• Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 7(2), 145–148 (2009).
   PubMed Web of Science ®Google Scholar
• Furuta K, Adachi K, Ohara S et al. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study. J. Int. Med. Res. 38(4), 1473–1483 (2010).
   PubMed Web of Science ®Google Scholar
• Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. Comparison of the Etest and the NCCLS–approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int. J. Antimicrob. Agents 17(1), 39–44 (2001).
   PubMed Web of Science ®Google Scholar
• Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur. J. Gastroenterol. Hepatol. 25(10), 1134–1140 (2013).
   PubMed Web of Science ®Google Scholar
• Liang X, Xu X, Zheng Q et al. Efficacy of Bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin. Gastroenterol. Hepatol. 11(7), 802–807 (2013).
   PubMed Web of Science ®Google Scholar
• Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 16(4), 295–300 (2011).
   PubMed Web of Science ®Google Scholar
• Dore MP, Graham DY, Mele R et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 97(4), 857–60 (2002).
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi. J. Gastroenterol. 18(1), 1–2 (2012).
   PubMed Web of Science ®Google Scholar
• Borody TJ, Pang G, Wettstein AR et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther. 23(4), 481–488 (2006).
   PubMed Web of Science ®Google Scholar
• Furuta T, Sugimoto M, Kodaira C et al. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of Helicobacter pylori. Hepatogastroenterology 57(102–103), 1314–1319 (2010).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob. Agents Chemother. 53(4), 1720–1721 (2009).
   PubMed Web of Science ®Google Scholar